Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Heidelberger, C., Chaudhuri, N., Danneburg, P., et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179: 663, 1957.
Bosch, L., Harbers, E., and Heidelberger, C. Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro. Cancer Res 18: 335, 1958.
Harbers, E., Chaudhuri, N., and Heidelberger, C. Studies on fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations. J Biol Chem 234: 1255, 1959.
Burchenal, J. The effects of halogenated pyrimidine derivatives on a spectrum of transplanted mouse leukemias. Proc Amer Assoc Cancer Res 2: 285, 1958.
Curreri, A., Ansfield, F., McIver, F., et al. Clinical studies with 5-fluorouracil. Cancer Res 18: 478, 1958.
Gold, G., Hall, T., Shnider, B., et al. A clinical study of 5-fluorouracil. Cancer Res 19: 935, 1959.
Olson, K., and Greene, J. Evaluation of 5-fluorouracil in treatment of cancer. J Nat Cancer Instit 25: 133, 1960.
Lemon, H. Reduction of 5-fluorouracil toxicity in man with retention of anticancer effect by prolonged intravenous administration in 5% dextrose. Cancer Chemother Rep 8: 97, 1960.
Wilson, W. Chemotherapy of human solid tumors with 5fluorouracil. Cancer 13: 1230, 1960.
Young, C., Ellison, R., Sullivan, R., et al. The clinical evaluation of 5-fluorouracil and 5-fluoro-2’-deoxyuridine in solid tumors in adults. A progress report. Cancer Chemother Rep 6: 17, 1960.
Allaire, F., Thieme, E., and Korst, D. Cancer chemotherapy with 5-fluorourà cil alone and in combination with x-ray therapy. Cancer Chemother Rep 14: 59, 1960.
Cornell, G., Cahow, C., Frey, C., et al. Clinical experience with 5-fluorouracil in the treatment of malignant disease. Cancer Chemother Rep 9: 23, 1960.
Krivit, W., and Bentley, H. Use of 5-fluorouracil in the management of advanced malignancies in childhood. Am J Dis Childh 100: 217, 1960.
Kennedy, B., and Theologides, A. The role of 5-fluorouracil in malignant disease. Ann Intern Med 55: 719, 1961.
Weiss, A., Jackson, L., and Carabasi, R. An evaluation of 5-fluorouracil in malignant disease. Ann Intern Med 55: 731, 1961.
Knoepp, L., Kastl, W., Rayburn, A., et al. Clinical experience with 5-fluorouracil. Cancer Chemother Rep 12: 89, 1961.
Staley, C., Keith, J., Cortes, N., et al. Treatment of advanced cancer with 5-fluorouracil. Surg Gyn and Obstet 112: 185, 1961.
Vaitkevicius, V., Brennan, M., Beckett, V., et al. Clinical evaluation of cancer chemotherapy with 5-fluorouracil. Cancer 41: 131, 1961.
Hurley, J., Ellison, E., and Carey, L. Treatment of advanced cancer of the gastrointestinal tract with antitumor agents. Gastroenterology 41: 557, 1961.
Hurley, J. Chemotherapy of colon tumors: panel discussion. (Cole, W.H., moderator). Am J Surg 103: 94, 1962.
Ansfield, F., Schroeder, J., and Curreri, A. Five years’ clinical experience with 5-fluorouracil. JAMA 181: 295, 1962.
Ellison, R. Experience with fluorinated pyrimidines in adenocarcinoma of the lower intestinal tract. N Y J Med 14: 2364, 1962.
Hyman, G., Ultmann, J., and Habif, D. Factors to be considered in the clinical evaluation of a new chemotherapeutic agent (5-fluorouracil). Cancer Chemother Rep 16: 397, 1962.
Curreri, A., and Ansfield, F. Comparison of 5-fluorouracil and 5-fluoro-2’-deoxyuridine in the treatment of far-advanced breast and colon lesions. Cancer Chemother Rep 16: 387, 1962.
Hall, B., and Good, J. Treatment of far-advanced cancer with 5-fluorouracil, used alone and in combination with irradiation. Incidence and duration of remission and survival-time data in 223 patients. Cancer Chemother Rep 16: 369, 1962.
Eyerly, R. The effects of 5-fluorouracil in patients with incurable cancer. Cancer Chemother Rep 20: 89, 1962.
Choy, D., Stylianou, S., and Hangul, A. Experience with 5fluorouracil in a variety of solid tumors. Cancer Chemother Rep 24: 99, 1962.
White, J., Ricketts, W., and Strudwick, W. A clinical study of 5-fluorouracil in a variety of far-advanced human malignancies. J Nat Med Assoc 54: 315, 1962.
Baines, C., and Ley, D. A preliminary report on the use of 5-fluorouracil in malignant disease. Canad Med Assoc J 86: 207, 1962.
Field, J. 5-fluorouracil treatment of advanced cancer in ambulatory patients. Cancer Chemother Rep 33: 45, 1963.
Dao, T., and Grinberg, R. Fluorinated pyrimidines in treatment of breast cancer patients with liver metastases. Cancer Chemother Rep 27: 71, 1963.
Glenn, J., Hunt, L., and Lathem, J. Chemotherapy of bladder carcinoma with 5-fluorouracil. Cancer Chemother Rep 27: 67, 1963.
Hartmann, J., Origenes, M., Murphy, M., et al. Effects of 2’-deoxy-5-fluorouridine and 5-fluorouracil on childhood leukemia. Cancer Chemother Rep 34: 51, 1964.
Moertel, C., Reitemeier, R., and Hahn, R. Fluorinated pyrimidine therapy of advanced gastrointestinal cancer. Gastroenterology 46: 371, 1964.
Ansfield, F. A less toxic fluorouracil dosage schedule. JAMA 190: 234, 1964.
Talley, R., Vaitkevicius, V., and Leighton, G. Comparison of cyclophosphamide and 5-fluorouracil in the treatment of patients with metastatic breast cancer. Clin Pharm Ther 6: 740, 1965.
Rochlin, D., Smart, C., and Silva, A. Chemotherapy of malignancies of the gastrointestinal tract. Am J Surg 109: 43, 1965.
Cressy, N., and Schell, H. 5-fluorouracil in glucose and saline: therapeutic effect and toxicity. Cancer Chemother Rep 9: 683, 1966.
Blokhina, N., and Blokhin, N. 5-fluorouracil therapy for cancer of the stomach. Cancer 20: 668, 1967.
Eastern Cooperative Group in Solid Tumor Chemotherapy. Comparison of antimetabolites in the treatment of breast and colon cancer. JAMA 200: 770, 1967.
Horton, J., Gehrt, P., Cunningham, T., et al. A comparison of combination and single drug chemotherapy in cancer of the colon, breast, and other organs. Proc Amer Assoc Cancer Res 8: 120, 1967.
Mackman, S., Ramirez, G., and Ansfield, F. Results of 5fluorouracil given by the multiple daily dose method in disseminated breast cancer. Cancer Chemother Rep 51: 483, 1967.
Moore, G., Bross, I., Ausman, R., et al. Effects of 5fluorouracil (NSC 19893) in 389 patients with cancer. Cancer Chemother Rep 52: 641, 1968.
Malkasian, G., Decker, D., Mussey, E., et al. Observations on gynecologic malignancy treated with 5-fluorouracil. Am J Ob Gyn 100: 1012, 1968.
Jacobs, E., Luce, J., and Wood, D. Treatment of cancer with weekly intravenous 5-fluorouracil. Cancer 22: 1233, 1968.
Ansfield, F., Ramirez, G., Mackman, S., et al. A ten-year study of 5-fluorouracil in disseminated breast cancer with clinical results and survival times. Cancer Res 29: 1062, 1969.
Moertel, C., Reitemeier, R., and Hahn, R. Comparative response of carcinoma of the rectum and carcinoma of the colon to fluorinated pyrimidine therapy. Cancer Chemother Rep 53: 283, 1969.
Hall, T., Cavins, J., Khung, C., et al. Time and vehicle studies of a safe and effective method for administration of 5-fluorouracil. Cancer 19: 1008, 1966.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1970 IFI/Plenum · New York-Washington-London
About this chapter
Cite this chapter
Livingston, R.B., Carter, S.K. (1970). 5-Fluorouracil. In: Single Agents in Cancer Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1378-6_9
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1378-6_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1380-9
Online ISBN: 978-1-4684-1378-6
eBook Packages: Springer Book Archive